U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C149H244N44O48S2
Molecular Weight 3483.9357
Optical Activity UNSPECIFIED
Defined Stereocenters 33 / 33
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KBP-042

SMILES

CC(C)C[C@@]([H])(C(=NCC(=N[C@@]([H])(CCCCN)C(=N[C@@]([H])(CC(C)C)C(=N[C@@]([H])(CO)C(=N[C@@]([H])(CCC(=N)O)C(=N[C@@]([H])(CCC(=O)O)C(=N[C@@]([H])(CC(C)C)C(=N[C@@]([H])(Cc1cnc[nH]1)C(=N[C@@]([H])(CCCCN)C(=N[C@@]([H])(CC(C)C)C(=N[C@@]([H])(CCC(=N)O)C(=N[C@@]([H])([C@@]([H])(C)O)C(=N[C@@]([H])(Cc2ccc(cc2)O)C(=O)N3CCC[C@@]3([H])C(=N[C@@]([H])(CCCNC(=N)N)C(=N[C@@]([H])([C@@]([H])(C)O)C(=N[C@@]([H])(CC(=O)O)C(=N[C@@]([H])(C(C)C)C(=NCC(=N[C@@]([H])(C)C(=N[C@@]([H])(CC(=N)O)C(=N[C@@]([H])(C)C(=O)N4CCC[C@@]4([H])C(=N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@]([H])(C(C)C)N=C([C@]5([H])CSSC[C@@]([H])(C(=N[C@@]([H])(CO)C(=N[C@@]([H])(CC(=N)O)C(=N[C@@]([H])(CC(C)C)C(=N[C@@]([H])(CO)C(=N[C@@]([H])([C@@]([H])(C)O)C(=N5)O)O)O)O)O)O)N=C(C)O)O)O

InChI

InChIKey=KRSXWFQIZOXHPX-XTWYBNIISA-N
InChI=1S/C149H244N44O48S2/c1-67(2)48-89(180-143(236)115(73(13)14)188-140(233)103-65-243-242-64-102(166-79(20)200)139(232)185-100(62-195)137(230)179-96(56-109(155)205)134(227)177-93(52-71(9)10)132(225)184-101(63-196)138(231)191-118(78(19)199)146(239)186-103)121(214)161-60-111(207)167-83(28-21-23-43-150)122(215)174-92(51-70(7)8)131(224)183-99(61-194)136(229)171-86(37-40-106(152)202)124(217)169-88(39-42-112(208)209)125(218)176-91(50-69(5)6)130(223)178-94(54-81-58-159-66-163-81)133(226)168-84(29-22-24-44-151)123(216)175-90(49-68(3)4)129(222)170-87(38-41-107(153)203)127(220)190-117(77(18)198)145(238)182-98(53-80-33-35-82(201)36-34-80)148(241)193-47-27-32-105(193)141(234)172-85(30-25-45-160-149(157)158)126(219)189-116(76(17)197)144(237)181-97(57-113(210)211)135(228)187-114(72(11)12)142(235)162-59-110(206)164-74(15)120(213)173-95(55-108(154)204)128(221)165-75(16)147(240)192-46-26-31-104(192)119(156)212/h33-36,58,66-78,83-105,114-118,194-199,201H,21-32,37-57,59-65,150-151H2,1-20H3,(H2,152,202)(H2,153,203)(H2,154,204)(H2,155,205)(H2,156,212)(H,159,163)(H,161,214)(H,162,235)(H,164,206)(H,165,221)(H,166,200)(H,167,207)(H,168,226)(H,169,217)(H,170,222)(H,171,229)(H,172,234)(H,173,213)(H,174,215)(H,175,216)(H,176,218)(H,177,227)(H,178,223)(H,179,230)(H,180,236)(H,181,237)(H,182,238)(H,183,224)(H,184,225)(H,185,232)(H,186,239)(H,187,228)(H,188,233)(H,189,219)(H,190,220)(H,191,231)(H,208,209)(H,210,211)(H4,157,158,160)/t74-,75-,76+,77+,78+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,114-,115-,116-,117-,118-/m0/s1

HIDE SMILES / InChI

Molecular Formula C149H244N44O48S2
Molecular Weight 3483.9357
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 33 / 33
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Jun 26 09:25:40 UTC 2021
Edited
by admin
on Sat Jun 26 09:25:40 UTC 2021
Record UNII
Q91PJI8O7T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KBP-042
Common Name English
KBP 042
Code English
UGP 302
Code English
UGP-302
Code English
L-PROLINAMIDE, N-ACETYL-L-CYSTEINYL-L-SERYL-L-ASPARAGINYL-L-LEUCYL-L-SERYL-L-THREONYL-L-CYSTEINYL-L-VALYL-L-LEUCYLGLYCYL-L-LYSYL-L-LEUCYL-L-SERYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-HISTIDYL-L-LYSYL-L-LEUCYL-L-GLUTAMINYL-L-THREONYL-L-TYROSYL-L-PRO
Systematic Name English
DACRA-042
Code English
Code System Code Type Description
PUBCHEM
138454980
Created by admin on Sat Jun 26 09:25:40 UTC 2021 , Edited by admin on Sat Jun 26 09:25:40 UTC 2021
PRIMARY
CAS
1432581-36-6
Created by admin on Sat Jun 26 09:25:40 UTC 2021 , Edited by admin on Sat Jun 26 09:25:40 UTC 2021
PRIMARY
FDA UNII
Q91PJI8O7T
Created by admin on Sat Jun 26 09:25:40 UTC 2021 , Edited by admin on Sat Jun 26 09:25:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
In vitro, KBP-042 demonstrated superior binding affinity and activation of amylin and calcitonin receptors, and ex vivo, KBP-042 exerted inhibitory action on stimulated insulin and glucagon release from isolated islets. In vivo, KBP-042 induced a superior and pronounced reduction in food intake in conjunction with a sustained pair-fed corrected weight loss in DIO rats. Concomitantly, KBP-042 improved glucose homeostasis and reduced hyperinsulinemia and hyperleptinemia in conjunction with enhanced insulin sensitivity. In ZDF rats, KBP-042 induced a superior attenuation of diabetic hyperglycemia and alleviated impaired glucose and insulin tolerance. These results could provide the basis for oral KBP-042 as a novel therapeutic agent in type 2 diabetes.
ACTIVE MOIETY
At the same time, s.c. KBP-042 suppressed the inappropriate glucagon response better than the oral formulation. Furthermore, KBP-042 was found to reduce incretins GLP-1 and GIP and considerably, improve gastric emptying, and to alleviate leptin resistance, as well as insulin resistance. In conclusion, the subcutaneous route of administration was found to have the same beneficial effects on blood glucose homeostasis and weight loss as well as resistance towards important insulin and leptin, albeit with a markedly lower variation in both exposure and biological responses. These data support the application of subcutaneously delivered peptide for mechanistic studies, and highlight the potential of developing s.c. KBP-042 as a therapy for T2D.